

AD_____

Award Number: W81XWH-05-1-0243

TITLE: Estrogen-Related Receptor Alpha (ERR α)-Coactivator Interactions as Targets
for Discovery of New Anti-Breast Cancer Therapeutics

PRINCIPAL INVESTIGATOR: Richard R. Burgess, Ph.D.

CONTRACTING ORGANIZATION: University of Wisconsin
Madison, WI 53706-1599

REPORT DATE: March 2006

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-03-2006		2. REPORT TYPE Annual		3. DATES COVERED (From - To) 15 Feb 2005 - 14 Feb 2006	
4. TITLE AND SUBTITLE Estrogen-Related Receptor Alpha (ERR α)-Coactivator Interactions as Targets for Discovery of New Anti-Breast Cancer Therapeutics				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-05-1-0243	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Richard R. Burgess, Ph.D. E-mail: rburgess@wisc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Wisconsin Madison, WI 53706-1599				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The nuclear receptor estrogen receptor alpha (ER α) is a primary focus of the therapy of breast cancers. ER α -positive breast cancers have traditionally been treated with the anti-estrogen tamoxifen, or with inhibitors of aromatase. ER α -negative breast cancers do not respond to anti-estrogen treatment; instead, current therapeutics, such as Herceptin, have focused on the transmembrane tyrosine kinase receptor ErbB2 (HER2) because it is often overexpressed in ER α -negative tumors and correlates with a poor prognosis. Estrogen-related receptor α (ERR α) has sequence similarity to ER α , but ERR α does not bind estrogens. In some cases ERR α is constitutively active, which is likely determined not only by its interaction with coactivators, but also in part by post-translational modifications occurring via the ErbB2 (HER2) signaling pathways. Thus, ERR α probably plays a key role in the etiology and progression of a subset of breast cancers. We believe that the ERR α -coactivator interaction is a promising target for new chemotherapeutic drug development. We have generated and characterized a set of murine monoclonal antibodies for use in studying the biology of ERR α . We are now using some of those antibodies in gentle immunoaffinity chromatography to determine ERR α -associated proteins. Using <i>in vitro</i> assays, we will study the binding properties of ERR α with known coactivators like transcriptional intermediary factor 2 (TIF2), as well as any ERR α -associated proteins we may find during immunopurification. In the future, using a luminescence resonance energy transfer-based high-throughput screen previously developed in our laboratory, we hope to identify small molecules that interfere with the binding of ERR α with these coactivators.					
15. SUBJECT TERMS Estrogen-related receptor alpha (ERR α), gentle immunoaffinity chromatography, protein-protein interactions, Luminescence Resonance Energy Transfer (LRET)					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 12	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

Cover	
SF 298	2
Introduction	4
Body (Research Accomplishments).....	5
Key Research Accomplishments	10
Reportable Outcomes	11
Conclusions	11
References	12

INTRODUCTION

The nuclear receptor estrogen receptor alpha (ER α) is a primary focus of the therapy of breast cancers. Its transcriptional activity is modulated by its binding to the steroid hormone estrogen, which allows ER α to bind estrogen response elements (EREs) in gene promoter regions. Many of its target genes, such as progesterone receptor (PgR), are involved in cell proliferation, and deregulation of ER α can lead to uncontrolled cellular growth and the promotion of breast cancer. ER α -positive breast cancers have a better prognosis and have traditionally been treated with the anti-estrogen tamoxifen, or with inhibitors of aromatase, an enzyme involved in estrogen synthesis. ER α -negative breast cancers, which occur in 25% of patients, do not respond to anti-estrogen treatment. Current therapeutics for ER α -negative cancers, such as Herceptin, have focused on ErbB2 (HER2) as a target because this transmembrane tyrosine kinase receptor is often overexpressed in ER α -negative tumors and correlates with a malignant phenotype and poor prognosis. Estrogen-related receptor α (ERR α) is a protein with sequence similarity to estrogen receptor α (ER α), but ERR α does not bind estrogens. However, ERR α can still bind to estrogen-response elements (EREs) in the promoter region of certain genes, and in some cases function as a constitutive activator, with its activity likely determined not only by its interaction with coactivator proteins, but also in part by post-translational modifications occurring via the ErbB2 (HER2) signaling pathways. Thus, ERR α probably also plays an important role in the etiology and progression of a subset of breast cancers.

The long-term goal of this project is to find a new treatment for human breast cancers, particularly aggressive ones that have constitutively active ERR α and are ErbB2 (HER2) overexpressing, ER α -negative, or tamoxifen-resistant. We believe that the ERR α -coactivator interaction is a promising target for new chemotherapeutic drug development. Therefore, using gentle immunoaffinity chromatography, we will determine ERR α -associated proteins; using *in vitro* assays, we will study the binding properties of ERR α with coactivators; and using a luminescence resonance energy transfer (LRET)-based high-throughput screen previously developed in our laboratory, we will identify small molecules that interfere with the binding of ERR α with these coactivators.


BODY (RESEARCH ACCOMPLISHMENTS)

Task 1: Determine ERR α -associated proteins.

Previously reported findings: We reported that we were in the process of producing murine monoclonal antibodies (mAbs) to estrogen-related receptor alpha (ERR α).


Generation of monoclonal antibodies:

To make the immunogen, human cDNA of ERR α 1 was inserted into the overexpression plasmid pET28b(+) (Novagen). The human ERR α 1 gene with a C-terminal hexahistidine-tag was encoded and expressed from a T7 promoter in *Escherichia coli* and purified by a nickel-nitrilotriacetic acid (Ni-NTA) affinity column (Figure 1). Using standard hybridoma techniques, a panel of murine mAbs was produced to the hexahistidine-tagged ERR α . Nine of those mAbs were tested for specificity in a Western blot (Figure 2).



← **Figure 1.** Stained SDS-PAGE of Ni-NTA affinity column purification of C-terminally hexahistidine-tagged ERR α expressed in *E. coli* BL21(DE3) cells.

→ **Figure 2.** Composite Western blot of anti-ERR α mAbs from hybridoma supernatants binding to ERR α overexpressed in MCF-7 cells. Rabbit polyclonal antibody, called YC2, was developed previously in the Mertz laboratory.



Polyol-responsiveness of the monoclonal antibodies:

The nine mAbs were tested to see if any were polyol-responsive, meaning the mAb binds its antigen tightly but releases it under gentle, non-denaturing conditions in the presence of an aqueous buffer at neutral pH supplemented with a low-molecular-weight polyhydroxylated compound (polyol) and a non-chaotropic salt. We have shown that the advantages of using polyol-responsive monoclonal antibodies (PR-mAbs) during immunoaffinity chromatography are two-fold: enzymes eluted under these gentle conditions retain their biological activity; and protein complexes maintain their structural integrity, allowing subsequent purification of any resulting multi-protein complex by size exclusion or ion exchange chromatography (for review, see Burgess and Thompson, 2002). In our experience, about 5-10% of all mAbs are polyol-responsive; however, we were pleasantly surprised to find that five of the nine tested anti-ERR α mAbs were polyol-responsive (Table 1). In a modified ELISA assay, these five antibodies bound tightly to 96-well polystyrene plates that had been coated with His-tagged ERR α and blocked with 1% dry milk in phosphate-buffered saline, but the mAbs were released from the antigen in the presence of a buffer (50 mM Tris-HCl, pH 7.9, 0.1 mM EDTA) containing the following four tested salt/polyol combinations: 0.75 M ammonium sulfate and 40% propylene

glycol; 0.75 M ammonium sulfate and 40% ethylene glycol; 0.75 M sodium chloride and 40% propylene glycol; 0.75 M sodium chloride and 40% ethylene glycol.

Most recent findings: We have made significant progress and are very near the completion of extensively characterizing this set of nine mAbs. We felt it was critical to know some of the properties before proceeding to use these antibodies in gentle immunoaffinity chromatography.

Epitope mapping of the monoclonal antibodies:

Using Western blot, we have been able to roughly determine the epitope of five of the nine mAbs. Figure 3 shows examples of the mapping of two mAbs. Equal amounts of MCF-7 whole cell extract containing various versions of overexpressed ERR α (Figure 3A) was separated by SDS-PAGE and transferred onto nitrocellulose membrane. In Figure 3B, left, mAb 2ERR10, purified from ascites fluid, was used as the primary antibody in the Western blot at a concentration of approximately 1 μ g/ml. In Figure 3B, right, mAb 2ERR7 hybridoma supernatant, at a dilution of 1:3, was used as the primary antibody in the Western blot. In both cases, a horseradish peroxidase-conjugated goat-anti-mouse IgG secondary antibody was used at a concentration of 1 μ g/ml. ECL reagents were used for detection. mAb 2ERR10 reacts with full-length ERR α , 1-376, 1-198, and 1-173, but does not interact with ERR α 77-423. This pattern suggests that the epitope of mAb 2ERR10 is in the N-terminus of ERR α , specifically between amino acids 1-76. In a similar analysis, mAb 2ERR7 interacts with full-length ERR α , 1-376, and 77-423, but it does not interact with ERR α 1-198 or 1-173, suggesting that its epitope is between amino acids 199-376. All other antibodies were subjected to the same analysis as these two antibodies, and similar patterning was seen (Western blots not shown).




Figure 3. (A) ERR α constructs transiently transfected into MCF-7 cells. Amino acids 1-423 is full length protein. ERR α 1-376 has the far C-terminal activation function 2 (AF2) region, a common protein-protein interaction site with the p160 coactivators, removed. ERR α 1-198 has the entire ligand binding domain (LBD) removed, whereas ERR α 1-173 has in addition part of the hinge region removed. Lastly, ERR α 77-423 has the A/B domain removed, which includes the AF1 region, another common site of protein-protein interactions. All constructs contain the DNA binding domain (DBD). **(B)** Western blot using either purified mAb (e.g. 2ERR10) or hybridoma supernatants (e.g. 2ERR7) and binding to versions of ERR α overexpressed in MCF-7 whole cell extracts. Equal amount of total whole cell extract protein was loaded in each lane.

Immunoprecipitation using the monoclonal antibodies:

We next wanted to see if the mAbs could work in immunoprecipitation experiments, which we thought would represent “mini” immunoaffinity columns and therefore give us some insight as to which mAb would work in our larger gentle immunoaffinity chromatography

procedure. Figure 4 shows one example of the immunoprecipitation experiment performed. Vero cells, which are African green monkey kidney cells and seem to be ERR α -negative, were transiently transfected with full-length ERR α . Cells were collected 48-hours post-transfection, and whole cell extract was produced. Anti-ERR α mAbs (e.g. 2ERR10) were attached to anti-mouse IgG-coated magnetic beads (Novagen). This bead/antibody complex was added to Vero whole cell extract and allowed to incubate at room temperature for one hour. The beads were extensively washed with phosphate-buffered saline and then boiled in SDS-loading buffer. The samples were run on SDS-PAGE and proteins were transferred to nitrocellulose. The membrane was blocked with 5% dry milk in phosphate-buffered saline. An anti-ERR α rabbit polyclonal antibody, called YC2 and developed in the Mertz laboratory, was used at a concentration of




Figure 4. Immunoprecipitation using mAb 2ERR10 of either Vero whole cell extract (Vero) or Vero whole cell extract containing overexpressed full-length ERR α (Vero/ ERR α). Western blot using anti-ERR α rabbit polyclonal antibody YC2.

approximately 1 μ g/ml as the primary antibody in the Western blot. A horseradish peroxidase-conjugated goat anti-rabbit IgG, at 0.2 μ g/ml concentration, was used as the secondary antibody, and ECL reagents were used in the detection. As seen in Figure 4, mAb 2ERR10 specifically precipitates ERR α from the Vero whole cell extract. mAbs 1ERR21 and 1ERR87 were tested in a similar way and also found to specifically pull-down ERR α . Unfortunately, 2ERR6 does not seem to be able to pull-down ERR α from a whole cell extract, although we are in the process of repeating this experiment with this antibody as well as finishing these immunoprecipitation experiments with the rest of the mAbs.

Size-exclusion chromatography and analysis using the monoclonal antibodies:

In preparation for producing immunoaffinity columns, we are generating larger quantities of the polyol-responsive mAbs by either growing the hybridoma cells in cell culture flasks or by producing ascites fluid in mice, and isolating the antibodies using standard purification techniques. Already, we have purified tens of milligram quantities of 1ERR21, 2ERR1, 2ERR6, 2ERR10, and 2ERR37. Immunoaffinity chromatography resins will be produced by using cyanogen-bromide activated Sepharose 4B (Sigma-Aldrich) to covalently attach the mAbs to the resin using methods described in Thompson and Burgess (2001). We are also isolating HeLa nuclear extract. We have received a generous gift of nuclear extract from 12 L of HeLa cell culture from Dr. Al Courey at UCLA. We also plan on purchasing more HeLa cell nuclei from the National Cell Culture Center. We have run preliminary experiments for determining the complexes in which ERR α is participating in HeLa cells. HeLa nuclear extract was run over a size exclusion column (Sephacryl S300), and fractions were collected. Samples of the fractions were dotted onto nitrocellulose, which was then blocked with 1% dry milk in phosphate-buffered saline. Fluorescently-labeled




Figure 5. Dot blot (Western blot) of fractions # 14-24 collected from size exclusion chromatography. Fluorescently labeled mAb 2ERR10, at 1 μ g/ml final concentration, was used as the immunodetection agent. Thyroglobulin, catalase, and chymotrypsinogen A are known molecular weight markers. A fluorimager was used for detection.

mAb 2ERR10 was used as the immunodetection reagent in the Western blot shown in Figure 5. Based on the elution of known molecular weight markers (thyroglobulin, catalase, and chymotrypsinogen A) from the column, it appears that ERR α is predominantly in a complex of approximately 250 kDa in HeLa nuclear extract.

Supershift assays using the monoclonal antibodies:

We have recently determined which of the mAbs can supershift a protein-DNA complex in electrophoretic mobility shift assays (EMSAs) (Figure 6). MCF-7 whole cell extract overexpressing full-length ERR α was incubated with or without purified mAb or mAb-enriched ascites fluid. The monoclonal antibody NT73, specific to *Escherichia coli* RNA polymerase subunit β' , was used as a negative control; the anti-ERR α polyclonal antibody YC2 was used as a positive control. The protein or protein-Ab complexes were then incubated with a radiolabeled DNA probe containing the consensus steroidogenic factor 1 response element (SFRE) sequence. Samples were run on native gels, exposed to a phosphorimager screen, and visualized on a Storm Imager. As shown in Figure 6, 1ERR87, 1ERR90, 2ERR1, and 2ERR10 can supershift the ERR α -DNA complex, but 1ERR21, 2ERR6, 2ERR7, and 2ERR37 cannot shift the complex. We are encouraged by these results, and we are now determining if these mAbs can supershift an ERR α -DNA complex in different whole cell extracts, such as BT-474 and HeLa cells, where ERR α is known to be a constitutive activator of transcription.




Figure 6. Supershift assay using anti-ERR α mAbs (Ab), either purified (P) or enriched ascites fluid (AF); MCF-7 whole cell extract (WCE) overexpressing full-length ERR α ; and a radiolabeled DNA probe (Probe) containing the steroidogenic factor response element (SFRE). Equal amounts of mAb, whole cell extract, and probe were added to each lane.

Immunohistochemistry and chromatin immunoprecipitation:

Lastly, we started a collaboration in November 2005 with Dr. Anastasia Kralli at The Scripps Research Institute to test some of our mAbs in immunohistochemistry (IHC) and chromatin immunoprecipitation (ChIP) experiments. We look forward to seeing those results.

Table 1. Summary of anti-ERR α monoclonal antibody characterization

mAb	1ERR21	1ERR87	1ERR90	2ERR1	2ERR2	2ERR6	2ERR7	2ERR10	2ERR37
Purified?	Yes	Yes	No	Yes	No	Yes	No	Yes	Yes
Isotype	IgG ₁	IgG ₁	IgG ₁	IgG _{2a}	IgG _{2a}	IgG _{2b}	IgG _{2b}	IgG ₁	IgG ₁
WB	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
PR-mAb	Yes	No	No	Yes	No	Yes	No	Yes	Yes
Epitope	199-376	1-76	1-76	nd	nd	nd	199-376	1-76	nd
IP	Yes	Yes	nd	nd	nd	No	nd	Yes	nd
Supershift	No	Yes	Yes	Yes	nd	No	No	Yes	No
IHC *									
ChIP *									

ERR α : A 423-amino acid nuclear receptor protein related to estrogen receptor.

Purified: purified from ascites fluid using methods previously described in Thompson and Burgess (2001).

Isotype: Type of immunoglobulin heavy chain; antibody subtype.

WB: Western blot; suitable for use in immunoblotting to detect protein expression.

PR-mAb: Polyol-responsive monoclonal antibody; able to bind antigen with high affinity but release under non-denaturing conditions.

Epitope: Location of mAb binding site on full-length ERR α (amino acids 1-423); region from amino acid # to amino acid #.

IP: Immunoprecipitation; suitable for use in immunoprecipitation to isolate ERR α and any associated proteins from cell extracts.

Supershift: Able to detect ERR α in its DNA-bound form in a gel shift assay.

IHC: Immunohistochemistry; useful in identifying cells in a tissue sample that contain ERR α .

ChIP: chromatin immunoprecipitation; able to immunoprecipitate ERR α in its chromatin-bound form from cell extracts.

nd: not determined.

* Will be determined in collaboration with Dr. Anastasia Kralli, of The Scripps Research Institute

Task 2: Study the binding properties of ERR α and its coactivators.

Because we have not yet isolated a transcriptional complex containing ERR α and its associated proteins (Task 1), we have not been able to start Task 2. We are, however, beginning to study the binding properties of ERR α and a member of the p160 family of transcriptional coactivators, TIF2. Please see our research accomplishments in Task 3 for more details.

We have added to our knowledge of ERR α 's transcriptional activity in another breast cancer cell type: SK-BR-3. The Mertz laboratory has previously published that in MCF-7 cells full-length ERR α is a repressor of ERE-dependent transcription, and in BT-474 cells ERR α is a constitutive activator of ERE-dependent transcription (Kraus *et al.*, 2002). We have found that in SK-BR-3 cells, full-length ERR α is a repressor of ERE-dependent transcription; however, an N-terminal truncation of ERR α , in the presence of the coactivator GRIP1 (TIF2, SRC-2), is an activator of ERE-dependent transcription. Please see our research accomplishments in Task 3 for more details on this N-terminal truncation of ERR α .

Task 3: Develop a high-throughput screen for molecules that interfere with the binding of ERR α and a coactivator.

It has been well-established in the Mertz laboratory that in MCF-7 cells ERR α functions as a repressor of transcription, and in BT-474 cells ERR α functions as a constitutive activator of transcription. However, very new and exciting unpublished transcriptional data from the Mertz laboratory suggests a N-terminal truncated version of ERR α converts ERR α from a repressor to

an activator in MCF-7 cells on an ERE-luciferase reporter gene. This suggests that there is a repressor motif in the N-terminus of ERR α . Unfortunately, we have not yet been able to co-immunoprecipitate the N- and C-terminus of ERR α using our monoclonal antibodies, which suggests that (1) we may have not yet optimized the proper binding conditions, or (2) there may be a bridging protein required for the N- and C-terminus of ERR α to interact.

The Mertz laboratory has additionally found that GRIP1, but not the other p160 family of transcriptional coactivators SRC-1 or SRC-3, is a major coactivator of full-length ERR α in BT-474 cells, where ERR α is known to be constitutively active. GRIP1, but again not SRC-1 or SRC-3, is also the major coactivator of the N-terminal truncated ERR α in MCF-7 cells. In both BT-474 and MCF-7 cells, GRIP1 further potentiates transcription of ERR α on an ERE-luciferase reporter gene, but most interestingly GRIP1 does *not* increase ERR α 's transcriptional activity on an SFRE-luciferase reporter gene. This observation suggests that ERR α specifically interacts with GRIP1 only when it is bound to an ERE; in other words, the ERR α /GRIP1 interaction is ERE-dependent. Other researchers have been able to show a protein-protein interaction of GRIP1 and ERR α in GST-pulldown experiments and have supported our observation that ERR α /GRIP1 interactions activate transcription synergistically in transient transfection assays (Xie *et al.*, 1999; Lu *et al.*, 2001; Zhang and Teng, 2001).

We are encouraged by these findings and would like to pursue this protein-protein interaction as a target for new chemotherapeutic development. We are currently cloning the human homolog of murine GRIP1, transcriptional intermediary factor 2 (TIF2), into bacterial and mammalian expression vectors. TIF2 and GRIP1 share 90% sequence similarity and are often substituted for one another in experiments; nevertheless, we would like to work with human proteins if we are to develop new anti-breast cancer therapeutics. We will characterize the transcriptional activity of TIF2 and ERR α , which we believe will be very similar to GRIP1 and ERR α . We hope to soon begin working on Tasks 2 and 3 with the ERR α /TIF2 protein-protein interaction.

We hope to start a cell-based high-throughput screen with the Small Molecule Screening Facility at the UW-Comprehensive Cancer Center on campus within the next 4-6 months. We will co-transfect TIF2, ERR α (or truncated ERR α), and an ERE-luciferase reporter plasmid into BT-474 cells (or MCF-7 cells). We will screen for small molecules that interfere with ERR α /TIF2 interaction and thus inhibit transcription of the reporter plasmid and decrease overall luciferase activity.

KEY RESEARCH ACCOMPLISHMENTS

- We have prepared a set of nine murine monoclonal antibodies against ERR α .
- We have characterized these mAbs extensively.
- We have started to study the interaction of ERR α with TIF2, a member of the p160 family of transcriptional coactivator proteins.

REPORTABLE OUTCOMES

Jennifer A. Lamberski

Abstracts:

- Great Lakes Nuclear Receptor Conference; Madison, WI; October 15, 2005
- The Keystone Symposia, Nuclear Receptors: Orphan Brothers; Banff, Alberta, Canada; March 18-23, 2006

Additional funding:

- Vilas Travel Award from the University of Wisconsin-Madison (\$600 award for travel to the Keystone Symposia)

Licenses:

- Disclosed the anti-ERR α mAbs to the University of Wisconsin-Madison patenting and licensing group, WARF

Poster Sessions:

- Great Lakes Nuclear Receptor Conference; Madison, WI; October 15, 2005
- The Keystone Symposia, Nuclear Receptors: Orphan Brothers; Banff, Alberta, Canada; March 18-23, 2006

Presentations:

- Cancer Biology Student/Postdoc Seminar Series; February 1 and December 20, 2005
- Molecular and Cellular Pharmacology Student Seminar Series; April 11 and December 5, 2005
- Nuclear Receptor Group meeting, September 30, 2005

CONCLUSIONS

We have made significant progress this year in generating and characterizing nine murine monoclonal antibodies against ERR α . We have determined their isotypes, epitopes, and polyol-responsiveness, and have tested the antibodies in a variety of assays including Western blot, immunoprecipitation, supershift, immunohistochemistry, and chromatin immunoprecipitation. Importantly, we have identified the antibodies most likely to work in gentle immunoaffinity chromatography, which will help us complete Task 1, finding ERR α associated proteins.

The Mertz laboratory has recently produced data suggesting that ERR α /GRIP1 interactions are important in driving ERE-dependent transcription in breast cancer cells. We look forward to pursuing this idea further by cloning the human homolog of GRIP1 into bacterial and mammalian expression vectors and studying its binding interactions with ERR α . This will help us continue our research in Tasks 2 and 3, studying the binding interactions of ERR α and a coactivator protein and developing a high-throughput screen for small molecules that interfere with this interaction.

REFERENCES

- Burgess RR, Thompson NE. Advances in gentle immunoaffinity chromatography. *Curr Opin Biotechnol* 13: 304-308, 2002.
- Kraus RJ, Ariazi EA, Farrell ML, Mertz JE. Estrogen-related receptor α 1 actively antagonizes estrogen receptor-regulated transcription in MCF-7 mammary cells. *J Biol Chem* 277: 24826-24834, 2002.
- Lu D, Kiriya Y, Lee KY, Giguère V. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. *Cancer Res* 61: 6755-6761, 2001.
- Thompson NE, Burgess RR. Identification of polyol-responsive monoclonal antibodies for use in immunoaffinity chromatography. In: F.M. Ausubel et al. (Eds) *Current Protocols in Molecular Biology*, Vol.2. John Wiley & Sons, Inc., New York, NY, 11.18.1-11.18.9, 2001.
- Xie W, Hong H, Yang NN, Lin RJ, Simon CM, Stallcup MR, Evans RM. Constitutive activation of transcription and binding of coactivator by estrogen-related receptors 1 and 2. *Mol Endocrinol* 13: 2151-2162, 1999.
- Zhang Z, and Teng CT. Estrogen receptor alpha and estrogen receptor-related receptor alpha1 compete for binding and coactivator. *Mol Cell Endocrinol* 172: 223-233, 2001.